Literature DB >> 30232221

Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer.

Supriya Srinivasan1, Tulasigeri Totiger1, Chanjuan Shi2, Jason Castellanos3, Purushottam Lamichhane1, Austin R Dosch1, Fanuel Messaggio1, Nilesh Kashikar4, Kumaraswamy Honnenahally3, Yuguang Ban5, Nipun B Merchant1,6, Michael VanSaun1,6, Nagaraj S Nagathihalli7,6.   

Abstract

Although smoking is a significant risk factor for pancreatic ductal adenocarcinoma (PDAC), the molecular mechanisms underlying PDAC development and progression in smokers are still unclear. Here, we show the role of cyclic AMP response element-binding protein (CREB) in the pathogenesis of smoking-induced PDAC. Smokers had significantly higher levels of activated CREB when compared with nonsmokers. Cell lines derived from normal pancreas and pancreatic intraepithelial neoplasm (PanIN) exhibited low baseline pCREB levels compared with PDAC cell lines. Furthermore, elevated CREB expression correlated with reduced survival in patients with PDAC. Depletion of CREB significantly reduced tumor burden after tobacco-specific nitrosamine 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment, suggesting a CREB-dependent contribution to PDAC growth and progression in smokers. Conversely, NNK accelerated PanIN lesion and PDAC formation via GM-CSF-mediated activation of CREB in a PDAC mouse model. CREB inhibition (CREBi) in mice more effectively reduced primary tumor burden compared with control or GM-CSF blockade alone following NNK exposure. GM-CSF played a role in the recruitment of tumor-associated macrophages (TAM) and regulatory T cell (Treg) expansion and promotion, whereas CREBi significantly reduced TAM and Treg populations in NNK-exposed mice. Overall, these results suggest that NNK exposure leads to activation of CREB through GM-CSF, promoting inflammatory and Akt pathways. Direct inhibition of CREB, but not GM-CSF, effectively abrogates these effects and inhibits tumor progression, offering a viable therapeutic strategy for patients with PDAC.Significance: These findings identify GM-CSF-induced CREB as a driver of pancreatic cancer in smokers and demonstrate the therapeutic potential of targeting CREB to reduce PDAC tumor growth.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/21/6146/F1.large.jpg Cancer Res; 78(21); 6146-58. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30232221      PMCID: PMC6214726          DOI: 10.1158/0008-5472.CAN-18-0579

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation.

Authors:  S S Hecht; S G Carmella; M Chen; J F Dor Koch; A T Miller; S E Murphy; J A Jensen; C L Zimmerman; D K Hatsukami
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

2.  A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent.

Authors:  Christos Fountzilas; Ravi Chhatrala; Nikhil Khushalani; Wei Tan; Charles LeVea; Alan Hutson; Chris Tucker; Wen Wee Ma; Graham Warren; Patrick Boland; Renuka Iyer
Journal:  Cancer Chemother Pharmacol       Date:  2017-07-12       Impact factor: 3.333

Review 3.  Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers.

Authors:  Courtney Schaal; Srikumar P Chellappan
Journal:  Mol Cancer Res       Date:  2014-01-07       Impact factor: 5.852

4.  Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.

Authors:  Nagaraj S Nagathihalli; Yugandhar Beesetty; Wooin Lee; M Kay Washington; Xi Chen; A Craig Lockhart; Nipun B Merchant
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

Review 5.  What turns CREB on?

Authors:  Mona Johannessen; Marit Pedersen Delghandi; Ugo Moens
Journal:  Cell Signal       Date:  2004-11       Impact factor: 4.315

6.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.

Authors:  Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

7.  GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer.

Authors:  Meghna Waghray; Malica Yalamanchili; Michele Dziubinski; Mina Zeinali; Marguerite Erkkinen; Huibin Yang; Kara A Schradle; Sumithra Urs; Marina Pasca Di Magliano; Theodore H Welling; Phillip L Palmbos; Ethan V Abel; Vaibhav Sahai; Sunitha Nagrath; Lidong Wang; Diane M Simeone
Journal:  Cancer Discov       Date:  2016-05-16       Impact factor: 39.397

8.  GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

Authors:  Gary Kohanbash; Kayla McKaveney; Masashi Sakaki; Ryo Ueda; Arlan H Mintz; Nduka Amankulor; Mitsugu Fujita; John R Ohlfest; Hideho Okada
Journal:  Cancer Res       Date:  2013-09-12       Impact factor: 12.701

9.  Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.

Authors:  Shintaro Takeuchi; Muhammad Baghdadi; Takahiro Tsuchikawa; Haruka Wada; Toru Nakamura; Hirotake Abe; Sayaka Nakanishi; Yuu Usui; Kohtaro Higuchi; Mizuna Takahashi; Kazuho Inoko; Syoki Sato; Hironobu Takano; Toshiaki Shichinohe; Ken-ichiro Seino; Satoshi Hirano
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

10.  Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.

Authors:  Emma M Kerr; Edoardo Gaude; Frances K Turrell; Christian Frezza; Carla P Martins
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

View more
  18 in total

1.  Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.

Authors:  Kinji Asahina; Steven Balog; Edward Hwang; Eugene Moon; Emily Wan; Kaitlin Skrypek; Yibu Chen; Jay Fernandez; Janet Romo; Qihong Yang; Keane Lai; Samuel W French; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-25       Impact factor: 4.052

2.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Authors:  Tulasigeri M Totiger; Supriya Srinivasan; Venkatakrishna R Jala; Purushottam Lamichhane; Austin R Dosch; Alexander A Gaidarski; Chandrashekhar Joshi; Shobith Rangappa; Jason Castellanos; Praveen Kumar Vemula; Xi Chen; Deukwoo Kwon; Nilesh Kashikar; Michael VanSaun; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Ther       Date:  2018-11-07       Impact factor: 6.261

3.  Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma.

Authors:  Na Qin; Yuancheng Li; Cheng Wang; Meng Zhu; Juncheng Dai; Tongtong Hong; Demetrius Albanes; Stephen Lam; Adonina Tardon; Chu Chen; Gary Goodman; Stig E Bojesen; Maria Teresa Landi; Mattias Johansson; Angela Risch; H-Erich Wichmann; Heike Bickeboller; Gadi Rennert; Susanne Arnold; Paul Brennan; John K Field; Sanjay Shete; Loic Le Marchand; Olle Melander; Hans Brunnstrom; Geoffrey Liu; Rayjean J Hung; Angeline Andrew; Lambertus A Kiemeney; Shan Zienolddiny; Kjell Grankvist; Mikael Johansson; Neil Caporaso; Penella Woll; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Victoria L Stevens; Guangfu Jin; David C Christiani; Zhibin Hu; Christopher I Amos; Hongxia Ma; Hongbing Shen
Journal:  Front Med       Date:  2020-09-05       Impact factor: 4.592

4.  LINC00857 promotes the proliferation of pancreatic cancer via MET, STAT3, and CREB.

Authors:  Ye Song; Yingying Liang; Qingfeng Zou; Shaoting Zeng; Hanhong Lin; Meiyuan Liu; Xiaoyan Liu; Jike Du; Guoan Chen; Lei Zou; Wenmei Su; Feiyu Niu
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 5.  Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer.

Authors:  Siddharth Mehra; Samara Singh; Nagaraj Nagathihalli
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

Review 6.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

7.  Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription.

Authors:  Jiangling Peng; Mark Miller; Bingbing X Li; Xiangshu Xiao
Journal:  ACS Med Chem Lett       Date:  2022-02-17       Impact factor: 4.632

8.  Mechanistic insights into the activation of ester prodrugs of 666-15.

Authors:  Fuchun Xie; Pedro Martín-Acosta; Bingbing X Li; Xiangshu Xiao
Journal:  Bioorg Med Chem Lett       Date:  2020-07-28       Impact factor: 2.823

9.  Histamine H3 Receptor Promotes Cell Survival via Regulating PKA/CREB/CDKN1A Signal Pathway in Hepatocellular Carcinoma.

Authors:  Chunle Zhang; Yang Yu; Liang Ma; Ping Fu
Journal:  Onco Targets Ther       Date:  2020-05-04       Impact factor: 4.147

Review 10.  IL-10 in glioma.

Authors:  Samuel S Widodo; Marija Dinevska; Liam M Furst; Stanley S Stylli; Theo Mantamadiotis
Journal:  Br J Cancer       Date:  2021-08-04       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.